Sijibio Signs Export Contracts for Adhesion Prevention Agent 'Mediclo' with Taiwan and Brazil

Sijibio Mediclo.

[Asia Economy Reporter Lee Gwan-joo] Siji Bio announced on the 16th that it has signed contracts worth approximately 5.6 billion KRW with Taiwanese medical device sales and distribution company CarePlusOne and Brazilian company OTIMA for the export of its adhesion prevention agent 'Mediclor (MEDICLO)' to Taiwan and Brazil.

An adhesion prevention agent is a product applied to prevent tissues or organs that are separated from adhering to each other. It is inserted into areas where adhesion is a concern after surgery, creating a kind of barrier to prevent them from sticking together. It is used in various surgical procedures such as spine, joint, mastectomy, gynecological surgery, prostatectomy, and gastrointestinal surgery.

Mediclor exists as a sol in liquid form at room temperature but changes to a highly viscous gel state due to body temperature after application inside the body. This characteristic allows it to remain firmly in place at sites where adhesion is expected after surgery, effectively preventing adhesion formation while the wound heals.

CEO Yoo Hyun-seung said, “The therapeutic materials markets in Taiwan and Brazil are among the markets with high growth potential, and we are pleased that Mediclor, an adhesion prevention agent with triple-effect and excellent technology, is entering these markets.” He added, “Going forward, Siji Bio will continue to research and develop innovative products based on regenerative medical technology to provide solutions that contribute to the healthy lives of patients worldwide.”

This content was produced with the assistance of AI translation services.